Anticholinergic Burden Comparison: Zuclopenthixol vs Chlorprothixene
Chlorprothixene has significantly higher anticholinergic burden than zuclopenthixol, making zuclopenthixol the preferred choice when anticholinergic effects are a concern.
Direct Anticholinergic Properties
Chlorprothixene possesses "weaker peripheral anticholinergic activity" as part of its core pharmacological profile 1, and demonstrates direct anticholinergic effects at the muscarinic receptor level, with documented inhibition of cholinergic-induced calcium signaling at concentrations as low as 1.9 μM 2. The FDA labeling explicitly warns about its anticholinergic effects and cautions use in patients with glaucoma or those receiving atropine 1.
In contrast, zuclopenthixol demonstrates minimal anticholinergic activity in clinical practice. While it shows high prescription persistence (69.8%), it requires concomitant anticholinergic antiparkinson drugs in 22.2% of patients 3, 4—but this reflects its dopaminergic blockade causing extrapyramidal symptoms requiring treatment, not inherent anticholinergic properties of the drug itself.
Clinical Implications for Cognitive Function
The 2025 INTEGRATE guidelines explicitly identify clozapine, olanzapine, and quetiapine as having the highest central anticholinergic activity among antipsychotics, with no mention of zuclopenthixol in this high-risk category 5. The guidelines recommend reviewing and minimizing anticholinergic burden specifically for cognitive symptoms, reinforcing that medications with lower anticholinergic properties should be preferred.
Recent 2025 pharmacological data confirms this hierarchy: using diphenhydramine as the reference standard (AE=1), medications with high anticholinergic equivalence include amitriptyline (AE: 8.99), clozapine (AE: 6.67), and olanzapine (AE: 3.08) 6. Neither zuclopenthixol nor chlorprothixene appear in the high-potency anticholinergic category, but chlorprothixene's documented muscarinic receptor antagonism places it at higher risk than zuclopenthixol.
Practical Prescribing Considerations
When choosing between these agents:
- For patients at risk of cognitive impairment, delirium, or falls (especially elderly): Choose zuclopenthixol over chlorprothixene
- For patients with glaucoma: Avoid chlorprothixene due to its anticholinergic effects 1; zuclopenthixol is safer
- For patients already on multiple medications: Zuclopenthixol contributes less to cumulative anticholinergic burden
The evidence consistently shows that while zuclopenthixol requires anticholinergic co-prescription for managing its extrapyramidal side effects in about 1 in 5 patients 4, this represents a treatable consequence of D2 antagonism rather than direct anticholinergic toxicity. Chlorprothixene's intrinsic anticholinergic properties cannot be mitigated and contribute directly to anticholinergic burden, cognitive impairment risk, and associated morbidity.
The mortality data further supports zuclopenthixol: While chlorprothixene showed elevated mortality risk (OR=1.34 compared to levomepromazine), zuclopenthixol demonstrated better safety profiles in long-term follow-up 3.